Sanofi Form 6-K June 04, 2013

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2013

Commission File Number: 001-31368

SANOFI

(Translation of registrant s name into English)

54, rue La Boétie, 75008 Paris, FRANCE

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F x Form 40-F o

Indicate by check mark if the regist	rant is submitting the Form 6-K i	in paper as permitted by Regulation S-T	Rule 101(b)(1): o
Indicate by check mark if the regist	rant is submitting the Form 6-K i	in paper as permitted by Regulation S-T	Rule 101(b)(7): o
Indicate by check mark whether the the Commission pursuant to Rule 1		rmation contained in this Form is also the change Act of 1934.	ereby furnishing the information to
	Yes o	No x	
If Yes marked, indicate below the	ne file number assigned to the reg	gistrant in connection with Rule 12g3-2(l	o): 82-

In June 2013, Sanofi issued the statement attached hereto as Exhibit 99.1 which is incorporated herein by reference.

Exhibit List

Exhibit No. Description

Exhibit 99.1 Press release dated June 3, 2013: Sanofi Provides Update on Phase 3 Studies of Two Investigational Compounds

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: June 4, 2013 SANOFI

By /S/ John Felitti

Name: John Felitti

Title: Associate Vice President,

Corporate Law, Financial & Securities Law

Exhibit Index

Exhibit No. Description

Exhibit 99.1 Press release dated June 3, 2013: Sanofi Provides Update on Phase 3 Studies of Two Investigational Compounds.